Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure

Authors:	Yuliy Y. Chirkov Michele De Sciscio Aaron L. Sverdlov Sue Leslie Peter R. Sage John D. Horowitz

Affiliation:	(1) Cardiology Unit, Vascular Disease and Therapeutics Research Group, Basil Hetzel Institute, The Queen Elizabeth Hospital, School of Medicine, The University of Adelaide, Adelaide, Australia;(2) Cardiology Unit, The Queen Elizabeth Hospital, Woodville 5011, Adelaide, S.A., Australia;

Abstract:	Purpose The A-HeFT trial demonstrated incremental survival with hydralazine/isosorbide dinitrate combination in African–American patients with chronic heart failure (CHF). It has been suggested that hydralazine might enhance nitric oxide (NO)—mediated effects of organic nitrates by decreasing superoxide (O₂⁻) formation, one of the factors inducing NO resistance. We evaluated whether hydralazine therapy potentiates nitrate-induced vasodilation and inhibition of platelet aggregation by ameliorating NO resistance.

Keywords:
本文献已被 SpringerLink 等数据库收录！